CN102614210A - 用于治疗结节性痤疮的阿奇霉素 - Google Patents
用于治疗结节性痤疮的阿奇霉素 Download PDFInfo
- Publication number
- CN102614210A CN102614210A CN2012100346744A CN201210034674A CN102614210A CN 102614210 A CN102614210 A CN 102614210A CN 2012100346744 A CN2012100346744 A CN 2012100346744A CN 201210034674 A CN201210034674 A CN 201210034674A CN 102614210 A CN102614210 A CN 102614210A
- Authority
- CN
- China
- Prior art keywords
- azithromycin
- acne
- treatment
- compositions
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010000496 acne Diseases 0.000 title claims abstract description 173
- 208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 160
- 229960004099 azithromycin Drugs 0.000 title claims abstract description 97
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 title claims abstract description 97
- 238000011282 treatment Methods 0.000 title claims abstract description 86
- 230000003203 everyday effect Effects 0.000 claims description 28
- 238000002560 therapeutic procedure Methods 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 20
- 238000007910 systemic administration Methods 0.000 claims description 10
- 239000002775 capsule Substances 0.000 claims description 6
- 230000000541 pulsatile effect Effects 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims 14
- VQEMDSRIOVZAOM-UHFFFAOYSA-N 4-(4-methylsulfonylphenyl)-1,3-thiazol-2-amine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CSC(N)=N1 VQEMDSRIOVZAOM-UHFFFAOYSA-N 0.000 claims 1
- 229960004924 azithromycin dihydrate Drugs 0.000 claims 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 25
- 229960004023 minocycline Drugs 0.000 description 25
- 238000011160 research Methods 0.000 description 23
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 22
- 229960005280 isotretinoin Drugs 0.000 description 22
- 239000003814 drug Substances 0.000 description 19
- 208000031513 cyst Diseases 0.000 description 15
- 210000003491 skin Anatomy 0.000 description 14
- FZKWRPSUNUOXKJ-CVHRZJFOSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydrate Chemical compound O.C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O FZKWRPSUNUOXKJ-CVHRZJFOSA-N 0.000 description 13
- 229960003722 doxycycline Drugs 0.000 description 13
- 230000003902 lesion Effects 0.000 description 13
- 206010011732 Cyst Diseases 0.000 description 12
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 11
- 230000003115 biocidal effect Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 230000006749 inflammatory damage Effects 0.000 description 9
- 230000002757 inflammatory effect Effects 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 206010037888 Rash pustular Diseases 0.000 description 8
- 239000004098 Tetracycline Substances 0.000 description 8
- 208000029561 pustule Diseases 0.000 description 8
- 229960002180 tetracycline Drugs 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 229930101283 tetracycline Natural products 0.000 description 7
- 235000019364 tetracycline Nutrition 0.000 description 7
- 208000035143 Bacterial infection Diseases 0.000 description 6
- 208000022362 bacterial infectious disease Diseases 0.000 description 6
- 229960003276 erythromycin Drugs 0.000 description 6
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 6
- 150000003522 tetracyclines Chemical class 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 230000003255 anti-acne Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000035935 pregnancy Effects 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 3
- 238000013196 antibiotherapy Methods 0.000 description 3
- 150000004683 dihydrates Chemical group 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 229930002330 retinoic acid Natural products 0.000 description 3
- 229940072172 tetracycline antibiotic Drugs 0.000 description 3
- 229960001727 tretinoin Drugs 0.000 description 3
- WTJXVDPDEQKTCV-VQAITOIOSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O WTJXVDPDEQKTCV-VQAITOIOSA-N 0.000 description 2
- 239000004342 Benzoyl peroxide Substances 0.000 description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 2
- 241000186427 Cutibacterium acnes Species 0.000 description 2
- 229920000832 Cutin Polymers 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 2
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229960002916 adapalene Drugs 0.000 description 2
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 description 2
- 229940061720 alpha hydroxy acid Drugs 0.000 description 2
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001745 anti-biotin effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 235000019400 benzoyl peroxide Nutrition 0.000 description 2
- 239000012459 cleaning agent Substances 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 150000004682 monohydrates Chemical group 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 229940055019 propionibacterium acne Drugs 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 150000004492 retinoid derivatives Chemical class 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- 229940102079 solodyn Drugs 0.000 description 2
- 229960000565 tazarotene Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- WTJXVDPDEQKTCV-UHFFFAOYSA-N 4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydron;chloride Chemical compound Cl.C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2C1CC1C(N(C)C)C(=O)C(C(N)=O)=C(O)C1(O)C2=O WTJXVDPDEQKTCV-UHFFFAOYSA-N 0.000 description 1
- 206010000503 Acne cystic Diseases 0.000 description 1
- 206010000513 Acne pustular Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010063655 Erosive oesophagitis Diseases 0.000 description 1
- 229930006677 Erythromycin A Natural products 0.000 description 1
- 206010050551 Lupus-like syndrome Diseases 0.000 description 1
- 241001459566 Papulosa Species 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 241000186429 Propionibacterium Species 0.000 description 1
- 208000035286 Spontaneous Remission Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000000589 cicatrix Anatomy 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011262 co‐therapy Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960002421 minocycline hydrochloride Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- QQVIHTHCMHWDBS-UHFFFAOYSA-N perisophthalic acid Natural products OC(=O)C1=CC=CC(C(O)=O)=C1 QQVIHTHCMHWDBS-UHFFFAOYSA-N 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- -1 tetracycline compound Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84906506P | 2006-10-03 | 2006-10-03 | |
| US60/849,065 | 2006-10-03 | ||
| US11/635,127 | 2006-12-06 | ||
| US11/635,127 US7704959B2 (en) | 2006-10-03 | 2006-12-06 | Azithromycin for the treatment of nodular acne |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007800406070A Division CN101534837B (zh) | 2006-10-03 | 2007-09-24 | 用于治疗结节性痤疮的阿奇霉素 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102614210A true CN102614210A (zh) | 2012-08-01 |
Family
ID=39261797
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007800406070A Expired - Fee Related CN101534837B (zh) | 2006-10-03 | 2007-09-24 | 用于治疗结节性痤疮的阿奇霉素 |
| CN2012100346744A Pending CN102614210A (zh) | 2006-10-03 | 2007-09-24 | 用于治疗结节性痤疮的阿奇霉素 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007800406070A Expired - Fee Related CN101534837B (zh) | 2006-10-03 | 2007-09-24 | 用于治疗结节性痤疮的阿奇霉素 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7704959B2 (enExample) |
| EP (2) | EP2086552B1 (enExample) |
| JP (1) | JP2010505827A (enExample) |
| KR (1) | KR20090064592A (enExample) |
| CN (2) | CN101534837B (enExample) |
| AT (1) | ATE533496T1 (enExample) |
| AU (1) | AU2007302663B2 (enExample) |
| BR (1) | BRPI0719535A2 (enExample) |
| CA (1) | CA2664673A1 (enExample) |
| CY (1) | CY1112650T1 (enExample) |
| DK (1) | DK2086552T3 (enExample) |
| ES (2) | ES2574677T3 (enExample) |
| MX (1) | MX2009003484A (enExample) |
| PL (2) | PL2086552T3 (enExample) |
| PT (1) | PT2086552E (enExample) |
| RU (1) | RU2009116629A (enExample) |
| SI (1) | SI2086552T1 (enExample) |
| WO (1) | WO2008042139A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8143227B2 (en) * | 2007-09-05 | 2012-03-27 | Dow Pharmaceutical Sciences, Inc. | Azithromycin for treatment of skin disorders |
| US8124123B2 (en) * | 2007-09-05 | 2012-02-28 | Dow Pharmaceutical Sciences, Inc. | Controlled release azithromycin solid dosages forms |
| CN107281155B (zh) * | 2017-06-06 | 2020-04-10 | 扬子江药业集团四川海蓉药业有限公司 | 一种阿奇霉素片及其制备方法 |
| CN111343991A (zh) * | 2017-07-21 | 2020-06-26 | 阿尔米雷尔有限责任公司 | 非炎性病变的治疗 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| YU43006B (en) | 1981-03-06 | 1989-02-28 | Pliva Pharm & Chem Works | Process for preparing n-methyl-11-aza-10-deoxo-10-dihydro erythromycin and derivatives thereof |
| US4474758A (en) | 1981-11-19 | 1984-10-02 | American Cyanamid Company | Haemophilus influenzae type b and pertussis outer membrane component combined vaccine |
| US4474768A (en) | 1982-07-19 | 1984-10-02 | Pfizer Inc. | N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor |
| US4474766A (en) | 1983-06-27 | 1984-10-02 | Merck & Co., Inc. | Anti-inflammatory/analgesic combination of cyclo-(N-methyl-Ala-Tyr-D-Trp-Lys-Val-Phe) and a selected non-steroidal anti-inflammatory drug (NSAID) |
| RO107257B1 (ro) | 1987-07-09 | 1993-10-30 | Pfizer | Procedeu de obtinere a unui dihidrat de azitromicina, cristalin |
| FR2710841B1 (fr) * | 1993-10-05 | 1995-11-17 | Oreal | Composition cosmétique ou pharmaceutique pour la peau, anhydre et stable, à base de rétinol et son utilisation en vue du traitement des maladies de la peau. |
| GB9723669D0 (en) * | 1997-11-07 | 1998-01-07 | Univ Aberdeen | Skin penetration enhancing components |
| US7211267B2 (en) | 2001-04-05 | 2007-05-01 | Collagenex Pharmaceuticals, Inc. | Methods of treating acne |
| WO2002080932A1 (en) * | 2001-04-05 | 2002-10-17 | Collagenex Pharmaceuticals, Inc. | Methods of treating acne |
| HRP20010301A2 (en) * | 2001-04-27 | 2001-12-31 | Pliva D D | New therapeutic indication for azithromycin in the treatment of non-infective inflammatory diseases |
| US9035741B2 (en) * | 2003-06-27 | 2015-05-19 | Stryker Corporation | Foot-operated control console for wirelessly controlling medical devices |
-
2006
- 2006-12-06 US US11/635,127 patent/US7704959B2/en not_active Expired - Fee Related
-
2007
- 2007-09-24 DK DK07838730.5T patent/DK2086552T3/da active
- 2007-09-24 BR BRPI0719535-4A patent/BRPI0719535A2/pt not_active IP Right Cessation
- 2007-09-24 SI SI200730804T patent/SI2086552T1/sl unknown
- 2007-09-24 RU RU2009116629/15A patent/RU2009116629A/ru unknown
- 2007-09-24 CN CN2007800406070A patent/CN101534837B/zh not_active Expired - Fee Related
- 2007-09-24 JP JP2009531388A patent/JP2010505827A/ja active Pending
- 2007-09-24 PL PL07838730T patent/PL2086552T3/pl unknown
- 2007-09-24 WO PCT/US2007/020583 patent/WO2008042139A2/en not_active Ceased
- 2007-09-24 ES ES11188960.6T patent/ES2574677T3/es active Active
- 2007-09-24 AT AT07838730T patent/ATE533496T1/de active
- 2007-09-24 PT PT07838730T patent/PT2086552E/pt unknown
- 2007-09-24 EP EP07838730A patent/EP2086552B1/en not_active Not-in-force
- 2007-09-24 MX MX2009003484A patent/MX2009003484A/es active IP Right Grant
- 2007-09-24 CA CA002664673A patent/CA2664673A1/en not_active Abandoned
- 2007-09-24 ES ES07838730T patent/ES2377470T3/es active Active
- 2007-09-24 PL PL11188960.6T patent/PL2420240T3/pl unknown
- 2007-09-24 AU AU2007302663A patent/AU2007302663B2/en not_active Ceased
- 2007-09-24 EP EP11188960.6A patent/EP2420240B1/en not_active Not-in-force
- 2007-09-24 KR KR1020097008632A patent/KR20090064592A/ko not_active Withdrawn
- 2007-09-24 CN CN2012100346744A patent/CN102614210A/zh active Pending
-
2010
- 2010-04-23 US US12/799,401 patent/US20100216732A1/en not_active Abandoned
-
2012
- 2012-01-17 CY CY20121100054T patent/CY1112650T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK2086552T3 (da) | 2012-01-09 |
| BRPI0719535A2 (pt) | 2014-01-14 |
| AU2007302663B2 (en) | 2012-07-12 |
| WO2008042139A3 (en) | 2008-10-16 |
| CN101534837B (zh) | 2012-04-04 |
| EP2086552A2 (en) | 2009-08-12 |
| EP2086552B1 (en) | 2011-11-16 |
| EP2086552A4 (en) | 2009-11-04 |
| SI2086552T1 (sl) | 2012-01-31 |
| PL2420240T3 (pl) | 2016-10-31 |
| WO2008042139A2 (en) | 2008-04-10 |
| HK1130667A1 (en) | 2010-01-08 |
| KR20090064592A (ko) | 2009-06-19 |
| AU2007302663A1 (en) | 2008-04-10 |
| US20100216732A1 (en) | 2010-08-26 |
| PL2086552T3 (pl) | 2012-03-30 |
| CA2664673A1 (en) | 2008-04-10 |
| MX2009003484A (es) | 2009-10-26 |
| JP2010505827A (ja) | 2010-02-25 |
| US7704959B2 (en) | 2010-04-27 |
| US20080081790A1 (en) | 2008-04-03 |
| PT2086552E (pt) | 2011-12-19 |
| RU2009116629A (ru) | 2010-11-10 |
| EP2420240A1 (en) | 2012-02-22 |
| ES2377470T3 (es) | 2012-03-27 |
| ES2574677T3 (es) | 2016-06-21 |
| EP2420240B1 (en) | 2016-05-11 |
| CN101534837A (zh) | 2009-09-16 |
| CY1112650T1 (el) | 2016-02-10 |
| ATE533496T1 (de) | 2011-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Goulden | Guidelines for the management of acne vulgaris in adolescents | |
| RU2490035C2 (ru) | Схема лечения заболеваний, связанных с акне | |
| US9132139B2 (en) | Maintenance therapy regime/regimen for the treatment of acne | |
| McKeage et al. | Doxycycline 40 mg Capsules (30 mg Immediate-Release/10 mg Delayed-Release Beads) Anti-Inflammatory Dose in Rosacea | |
| CN102614210A (zh) | 用于治疗结节性痤疮的阿奇霉素 | |
| Vercaigne et al. | Recommended treatment for urinary tract infection in pregnancy | |
| US20050158404A1 (en) | Composition and method for treatment of acne | |
| Gabaton et al. | A double-blind randomized controlled trial on the efficacy and safety of metformin as an adjunct to lymecycline and topical adapalene plus benzoyl peroxide gel in the treatment of moderate to severe acne vulgaris | |
| Alyasi et al. | Isotretinoin-induced thrombocytosis in a patient with acne vulgaris: a case report | |
| Magalhães et al. | Dietary omega‐3 fatty acids in the management of feline periodontal disease: What is the evidence? | |
| Mehlisch et al. | Analgesia with ibuprofen arginate versus conventional ibuprofen for patients with dysmenorrhea: a crossover trial | |
| Lin et al. | Onychotillomania, major depressive disorder and suicide | |
| HK1130667B (en) | Azithromycin for the treatment of nodular acne | |
| HK1162921A (en) | Azithromycin for the treatment of nodular acne | |
| Brandt et al. | Erythromycin acistrate-an alternative oral treatment for acne | |
| DiJoseph et al. | S3450 Optimal Inpatient Dosing of Proton Pump Inhibitors | |
| Buckley et al. | Isotretinoin therapy for acne vulgaris: results in an Irish population | |
| JP2008528538A (ja) | 尋常性座瘡の維持療法のためのアダパレン | |
| Koçak | A Randomized Double-Blind Study: Evulation of Comparing Intravenous Fentanyl with Intravenous Tramadol Administered to Patients with Pain Control Due to Urinary Stone Disease. | |
| CA3142876A1 (en) | Telmisartan for the treatment of chronic kidney disease in dogs | |
| Karpecki | Put dry eye treatment where your patient's mouth is: these oral medications may help treat your dry eye patients when drops aren't enough | |
| Statsenko et al. | Isotretinoin is the gold standard for acne therapy. Treating severe acne | |
| McIntyre et al. | 142: Iron-Magnesium Hydroxycarbonate (Alpharen): A Novel Non Calcium Containing Phosphate Binder for the Treatment of Hyperphosphataemia in Chronic Haemodialysis Patients | |
| Mc Causland et al. | 141: Prevalence of ACE Inhibitor and ARB Exposure in Acute Kidney Injury in a Tertiry Referral Centre | |
| McLaughlin et al. | 143: Intensive Education as a Quality Improvement Tool to Reduce Interdialytic Weight Gain (IDWG) in Chronic Hemodialysis (CHD) Patients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120801 |